Antimetastatic Effects of Thymoquinone in Colorectal Cancer: Targeting Cell Adhesion, Migration, and Invasion in SW480 and SW620 Models
Cell Biology International · 2026
DOI: 10.1002/cbin.70107 ↗At a glance
Journal article in Cell Biology International, 2026. Written by Mouna Selmi and 7 co-authors. Institution: Faculty of Dental Medicine of Monastir, Research laboratory of Bioactive Natural Products and Biotechnology LR24ES14, University of Monastir, Monasti…. Major MEDLINE topics: Colorectal Neoplasms, Cell Movement, Benzoquinones. 43 references. Funded by: The work was supported by the Tunisian Ministry of Higher Education and Scientific Research (TMHESR)..
Abstract (original language)
Thymoquinone (TQ), the major bioactive constituent of Nigella sativa , Asian and African medicinal plant, has attracted growing interest for its anticancer properties. In this study, we investigated the antimetastatic potential of TQ in human colorectal carcinoma (CRC) cell lines SW480 and SW620, representing primary and metastatic stages, respectively. The treatment with several concentration of TQ has significantly reduced cell adhesion to extracellular matrix proteins (fibronectin, collagen I and IV), without affecting adhesion to poly‐ l ‐lysine, proving disruption of integrin‐mediated attachment. Furthermore, wound healing and transwell migration assays demonstrated that TQ has significantly inhibited CRC cell motility and migratory capacity in a time‐ and dose‐dependent manner. Interestingly, our findings highlight the therapeutic potential of TQ in colorectal cancer by targeting tumor cell dissemination. Thus TQ may represent a promising candidate for the development of novel antimetastatic strategies as a nutraceutical compound in colorectal cancer therapy. Importantly, TQ treatment led to a marked, dose‐dependent decrease in MMP9 and MMP2 mRNA expression, as revealed by RT‐PCR and densitometric quantification. At the highest doses, MMP9 and MMP2 expression levels were reduced to 0.76‐ and 0.56‐fold (SW480, 30 μM) and to 0.73‐ and 0.61‐fold (SW620, 48 μM) relative to control, respectively. These findings demonstrate that TQ robustly inhibits the transcription of key metastasis‐associated markers in CRC cells.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Dental Medicine of Monastir, Research laboratory of Bioactive Natural Products and Biotechnology LR24ES14, University of Monastir, Monastir, Tunisia.
- Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
ORCID profiles: Mouna Selmi, Abir Salek
Funding
- The work was supported by the Tunisian Ministry of Higher Education and Scientific Research (TMHESR).
Cite
APA
Selmi, M., Salek, A., Barboura, M., Lahmar, A., Maatouk, M., Sioud, F., Boubaker, J., & Chekir-Ghedira, L. (2026). Antimetastatic Effects of Thymoquinone in Colorectal Cancer: Targeting Cell Adhesion, Migration, and Invasion in SW480 and SW620 Models. Cell Biology International. https://doi.org/10.1002/cbin.70107
Vancouver
Selmi M, Salek A, Barboura M, Lahmar A, Maatouk M, Sioud F, et al. Antimetastatic Effects of Thymoquinone in Colorectal Cancer: Targeting Cell Adhesion, Migration, and Invasion in SW480 and SW620 Models. Cell Biology International. 2026. doi:10.1002/cbin.70107
BibTeX
@article{Selmi2026,
author = {Selmi, Mouna and Salek, Abir and Barboura, Mahassen and Lahmar, Aida and Maatouk, Mouna and Sioud, Fairouz and Boubaker, Jihed and Chekir-Ghedira, Leila},
title = {Antimetastatic Effects of Thymoquinone in Colorectal Cancer: Targeting Cell Adhesion, Migration, and Invasion in SW480 and SW620 Models},
journal = {Cell Biology International},
year = {2026},
doi = {10.1002/cbin.70107}
}
EUVIMED